Birgit Schultes

Company: Intellia Therapeutics

Job title: Senior Vice President, Cell Therapy


Unlocking Allogeneic TCR Therapies to Pursue Wider Treatment Capability 1:30 pm

Achieving a durable allogeneic response to promote tumor persistence Preventing graft versus host disease to inhibit toxicity in vivo Ensuring TCR scalability to boost off-the-shelf manufacturingRead more

day: Conference Day Two

© Copyright 2023 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Eastcastle House, 27/28 Eastcastle Street, London, W1W 8DH.